Pharmabiz6d
Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate
Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate: San Francisco, US Friday, January 3, 2025, ...
조선일보6d
Roche secures cancer-fighting ADC from Innovent in $1 billion deal
Innovent Biologics announced on the 2nd (U.S. local time) that it has signed a global development and sales license (technology transfer) agreement with Roche for the ADC "IBI3009," which is being ...
High Growth Tech Stocks Innovent Biologics And 2 Other Promising Picks
Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress
Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...
FiercePharma6d
Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter
In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.
Innovent Biologics: Strategic Partnerships and Robust Pipeline Drive Buy Rating
Analyst Jill Wu of CMB International Securities maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), boosting the price ...
precisionmedicineonline6d
Innovent's Dovbleron Gains Approval in China for ROS1-Positive NSCLC
Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...